Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M.S. Bartlett, Christopher Poole, David Cameron et al.|The Lancet Oncology|2010Cited by 127
Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyJohn M.S. Bartlett, U Chetty, Jeremy Thomas et al.|Breast Cancer Research|2010Cited by 119
Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor–positive early breast cancer patientsJohanna G. H. van Nes, John M.S. Bartlett, Esther M. de Kruijf et al.|Breast Cancer Research and Treatment|2011Cited by 84